RT Journal Article
SR Electronic
T1 Viral loads and profile of the patients infected with SARS-CoV-2 Delta, Alpha or R.1 variants in Tokyo
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.21.21263879
DO 10.1101/2021.09.21.21263879
A1 Tani-Sassa, Chihiro
A1 Iwasaki, Yumi
A1 Ichimura, Naoya
A1 Nagano, Katsutoshi
A1 Takatsuki, Yuna
A1 Yuasa, Sonoka
A1 Takahashi, Yuta
A1 Nakajima, Jun
A1 Sonobe, Kazunari
A1 Nukui, Yoko
A1 Takeuchi, Hiroaki
A1 Tanimoto, Kousuke
A1 Tanaka, Yukie
A1 Kimura, Akinori
A1 Tohda, Shuji
YR 2021
UL http://medrxiv.org/content/early/2021/09/22/2021.09.21.21263879.abstract
AB The rapid spread of the Delta variant of SARS-CoV-2 became a serious concern worldwide in summer 2021. We examined the copy number and variant types of all SARS-CoV-2-positive patients who visited our hospital from February to August 2021 using PCR tests. Whole genome sequencing was performed for some samples. The R.1 variant (B.1.1.316) was responsible for most infections in March, replacing the previous variant (B.1.1.214); the Alpha (B.1.1.7) variant caused most infections in April and May; and the Delta variant (B.1.617.2) was the most prevalent in July and August. There was no significant difference in copy numbers among the previous variant cases (n=29, median 3.0×104 copies/μL), R.1 variant cases (n=28, 2.1×105 copies/μL), Alpha variant cases (n=125, 4.1×105 copies/μL), and Delta variant cases (n=106, 2.4×105 copies/μL). Patients with Delta variant infection were significantly younger than those infected with R.1 and the previous variants, possibly because many elderly individuals in Tokyo were vaccinated between May and August. There was no significant difference in mortality among the four groups. Our results suggest that the increased infectivity of Delta variant may be caused by factors other than the higher viral loads. Clarifying these factors is important to control the spread of Delta variant infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWGS was supported by grant JPMJCR20H2 from JST-CREST and grant 20nk0101612h0901 from the Japan Agency for Medical Research and Development.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Medical Research Ethics Committee of Tokyo Medical and Dental University (approval number: M2020-004) and was conducted in accordance with the ethical standards of the 1964 Helsinki Declaration.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data and protocol of RT‐PCR are available from the corresponding author upon request.